IL6 and rheumatoid arthritis: In rheumatoid arthritis, IL‐6 blockade using tocilizumab resulted in a decrease in the levels of IgG4 anticyclic citrullinated peptide (CCP) but not of IgG1 anti‐CCP or antinuclear antibodies (ANA) 28.